Richard T. Penson

Oncology

55 Fruit St
Boston, MA 02114

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 116 publications

Randomized clinical trial of an Acceptance and Commitment Therapy telehealth intervention ('REVITALIZE') to reduce fatigue interference in women with advanced ovarian cancer on PARP inhibitors: study protocol.

Randomized clinical trial of an Acceptance and Commitment Therapy telehealth intervention ('REVITALIZE') to reduce fatigue interference in women with advanced ovarian cancer on PARP inhibitors: study protocol.

Journal: BMC cancer

Published: March 24, 2026

Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial.

Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: October 16, 2025

Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial.

Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial.

Journal: Nature communications

Published: July 12, 2025

Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer.

Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer.

Journal: JCO precision oncology

Published: April 10, 2025

Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagers.

Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagers.

Journal: Signal transduction and targeted therapy

Published: March 16, 2025

Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer.

Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer.

Journal: Gynecologic oncology

Published: February 22, 2025

Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.

Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 12, 2024

The PRIMAry point: health-related quality of life (HRQoL).

The PRIMAry point: health-related quality of life (HRQoL).

Journal: Annals of palliative medicine

Published: November 27, 2024

Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.

Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.

Journal: Gynecologic oncology

Published: September 08, 2024

Long-Term Results of a Phase 2 Study of Adjuvant Proton Radiation Therapy for Node-Positive Cancer of the Uterus and Cervix.

Long-Term Results of a Phase 2 Study of Adjuvant Proton Radiation Therapy for Node-Positive Cancer of the Uterus and Cervix.

Journal: International journal of radiation oncology, biology, physics

Published: July 29, 2024

Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.

Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.

Journal: JCO precision oncology

Published: April 18, 2024

A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.

A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.

Journal: Gynecologic oncology

Published: March 24, 2024

Showing 1-12 of 116

Last Updated: 09/26/2026